【大河财立方消息】3月25日，药明生物在港交所公告称，2024年营收186.8亿元，比上年同期增长9.6%；净利润33.6亿元人民币，比上年同期下降1.3%，市场预估33.1亿元人民币。公司拥有人应占经调整纯利47.8亿元，同比增长1.8%。

　　费用方面，研发开支减少2.5%至约7.66亿元，主要由于WBS和数字化推动自动化并增强运营效率。销售及营销开支显著增长61.1%至约4.74亿元，主要由于公司扩大区域布局和增加市场宣传。行政开支增长11.9%至约人民币16.74亿元，主要由于员工相关成本和设施折旧增加。

（文章来源：大河财立方）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.